Acalabrutinib is a targeted therapy that inhibits the function of Bruton’s tyrosine kinase (BTK). BTK is a
Intracellular proteins may be overexpressed in malignant B cells. Acalabrutinib is a BTK inhibitor
agent that blocks BCR signaling and inhibits the growth and survival of malignant B-cell tumors.
Let us work together to protect precious health